Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
N Engl J Med. 2022;387(4):321–331 doi: 10.1056/NEJMoa2118024
Werth, et al. investigate the efficacy and safety of litifilimab, a humanised IgG1 monoclonal antibody against blood dendritic cell antigen 2 (BDCA2), in patients with moderate-to-severe subacute and chronic cutaneous lupus erythematosus, with or without systemic manifestations, with results showing superiority to placebo.